Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma
This is an open-label, multicenter Phase 1b/2a study to evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of GNS561 in combination with trametinib in Advanced KRAS Mutated Cholangiocarcinoma after failure of standard-of-care first line therapy
Cholangiocarcinoma
DRUG: GNS561 + Trametinib
Incidence of dose limiting toxicity (DLT) of GNS561 with trametinib (Phase 1b), Defined as Treatment Emergent Adverse Event (TEAE) being at least possibly related to study drug: With Grade â‰¥ 3 (using NCI CTCAE Version 5.0 or higher as applicable) such as specified in the protocol, At the end of Cycle 1 (each Cycle is 21 days)|Objective response rate (ORR) of the combination of GNS561 with trametinib (Phase 2a), Defined as the proportion of patients with a best overall response of complete response (CR) or partial response (PR) using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1), Up to 11 months (estimated)
Duration of response (DoR), Defined as the duration between first documentation of CR or PR to first documentation of disease progression or death using RECIST v1.1, Up to 11 months (estimated)|Progression-free survival (PFS), Defined as the time from the date of first dose of study drug to the date of first documented disease progression or death, Up to 11 months (estimated)|Time To Progression (TTP), Defined as the time from first dose of study drug to the date of first documented disease progression., Up to 11 months (estimated)|Disease Control Rate (DCR), defined as the proportion of patients with a best overall response of CR or PR or stable disease (SD) using RECIST v1.1, Up to 11 months (estimated)|Time To Response (TTR), Defined as the time from first dose of study drug to first documentation of CR or PR using RECIST v1.1, Up to 11 months (estimated)|Overall Survival (OS) time, Defined as the time from the date of first dose of study drug to the date of death due to any cause., Up to approximately 42 months|Incidence and severity of treatment emergent adverse event (TEAEs), incidence of serious adverse events (SAEs), incidence of TRAEs, incidence of adverse events of special interest (AESIs), rate of treatment discontinuation or interruption for TRAEs, graded according to NCI CTCAE v5.0, Up to 11 months (estimated)|Incidence of clinically significant changes or abnormalities from physical examinations, ophthalmologic assessments, vital signs, performance scores, laboratory results, ECGs, echocardiograms or multigated acquisition scans, Up to 11 months (estimated)|Drug concentration in plasma for GNS561 and trametinib, Predose to Day 21 of Cycle 1 and predose to Day 21 of Cycle 2 (each Cycle is 21 days)
This is an open-label, multicenter Phase 1b/2a study to evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of GNS561 in combination with trametinib in Advanced KRAS Mutated Cholangiocarcinoma after failure of standard-of-care first line therapy